A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX®), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers

Journal of Clinical Pharmacology

Volumn 40, Issue 12 II, 2000, Pages 1509-1515

  Greenberg, Howard E ^a   Gottesdiener, Keith ^b   Huntington, Martha ^b   Wong, Peggy ^b   Larson, Pat ^b   Wildonger, Lynn ^b   Gillen, Lisa ^a   Dorval, Ellen ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 2; ROFECOXIB; THROMBOXANE B2;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADOLESCENT; ADULT; ASPIRIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES; THROMBOXANE B2;

EID: 0033730933     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127000004001224     Document Type: Article

References (27)

1. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: Effects of interleukin-1β, phorbol ester, and corticosteroids
2. Human cyclooxygenase-2 cDNA
3. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells
4. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat preovulatory follicles: Induction in vivo and in vitro
5. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
6. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
7. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
8. Selective expression of mitogeninducible cyclooxygenase in macrophages stimulated with lipopolysaccharide
9. Involvement of tyrosine kinase in the induction of cyclooxygenase and nitric oxide synthase by endotoxin in cultured cells
10. Involvement of tyrosine kinases in the induction of cyclooxygenase-2 in human endothelial cells
11. Interleukin-1 differentially modulates chondrocyte expression of cyclooxygenase-2 and phospholipase A2
12. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
13. 2 stimulation
14. 2 and cyclooxygenase-2 expression by tracheobronchial smooth muscle cells
15. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic
16. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo
17. The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4
18. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
19. Cyclooxygenase-2 inhibitors: Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives
20. Pharmacology of a selective cyclooxygenase-2 inhibitor L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
21. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
22. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans
23. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase
24. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction
25. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects